Life Technologies Corporation
LIFE today announced that it has signed a five-year agreement with
the Food and Drug Administration (FDA) to accelerate and advance food safety
testing of E. coli and Salmonella, two foodborne contaminants commonly
associated with outbreaks and/or recalls.
The collaboration consists of three distinctive projects:
o Life Technologies will design and validate new food safety tests for the
detection and identification of foodborne pathogens, with pathogen strains
provided by the FDA.
o Life Technologies will design and validate a complete workflow for food
pathogen detection on the Ion PGM™ platform, while optimizing sample
preparation methods.
o The FDA will have the opportunity to evaluate new disruptive technology
platforms by Life Technologies for the use in pathogen detection.
Life Technologies will use its bioinformatics resources to independently
develop real-time PCR (polymerase chain reaction) assays against unique E.
coli and Salmonella targets in collaboration with the FDA. It will then
provide the test results for these targets to the FDA for further validation.
The FDA will use Life Technologies' Ion PGM™ Sequencer to generate whole
genome sequence information from defined bacteria, and for strains that will
be excluded from detection. Life Technologies' bioinformatics team will then
analyze the genomic information and provide assays or tests to the FDA for
further validation and analysis. Whole genome sequences generated under the
collaboration will be added to the National Institutes of Health Genbank so
they can be accessed by the food safety research community.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in